Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn’s disease by Diederen, Kay et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:18879  | https://doi.org/10.1038/s41598-020-75306-z
www.nature.com/scientificreports
Exclusive enteral nutrition 
mediates gut microbial 
and metabolic changes that are 
associated with remission 
in children with Crohn’s disease
Kay Diederen1,2, Jia V. Li3,7, Gillian E. Donachie5,7, Tim G. de Meij1,7, Dirk R. de Waart2, 
Theodorus B. M. Hakvoort2, Angelika Kindermann1, Josef Wagner6, Victoria Auyeung3,4, 
Anje A. te Velde2, Sigrid E. M. Heinsbroek2, Marc A. Benninga1, James Kinross3,4, 
Alan W. Walker5, Wouter J. de Jonge2 & Jurgen Seppen2*
A nutritional intervention, exclusive enteral nutrition (EEN) can induce remission in patients with 
pediatric Crohn’s disease (CD). We characterized changes in the fecal microbiota and metabolome 
to identify the mechanism of EEN. Feces of 43 children were collected prior, during and after EEN. 
Microbiota and metabolites were analyzed by 16S rRNA gene amplicon sequencing and NMR. 
Selected metabolites were evaluated in relevant model systems. Microbiota and metabolome of 
patients with CD and controls were different at all time points. Amino acids, primary bile salts, 
trimethylamine and cadaverine were elevated in patients with CD. Microbiota and metabolome 
differed between responders and non-responders prior to EEN. EEN decreased microbiota diversity 
and reduced amino acids, trimethylamine and cadaverine towards control levels. Patients with CD 
had reduced microbial metabolism of bile acids that partially normalized during EEN. Trimethylamine 
and cadaverine inhibited intestinal cell growth. TMA and cadaverine inhibited LPS-stimulated TNF-
alpha and IL-6 secretion by primary human monocytes. A diet rich in free amino acids worsened 
inflammation in the DSS model of intestinal inflammation. Trimethylamine, cadaverine, bile salts 
and amino acids could play a role in the mechanism by which EEN induces remission. Prior to EEN, 
microbiota and metabolome are different between responders and non-responders.
Exclusive enteral nutrition (EEN) is the treatment of choice for patients with pediatric Crohn’s disease (CD) in 
 Europe1. It is equally efficacious as corticosteroids in inducing clinical remission in children and adolescents 
with active  CD2,3 and superior in inducing mucosal  healing4. Despite solid evidence for efficacy of nutritional 
therapy in children, the mechanisms by which EEN induces remission remain elusive.
The gut microbiota and metabolomes of patients with CD are different from healthy  individuals5,6. The 
implication is that perturbed gut microbial co-metabolism could play an important role in the pathogenesis of 
CD. Indeed many studies showed that interactions between the gut microbiota, metabolites and the intestinal 
immune system are critical for maintenance of a healthy  intestine7. The intestinal microbiota of new-onset 
patients with pediatric CD typically exhibits a decreased microbial  diversity8, with lower relative abundance of 
Firmicutes9. Moreover, patients with CD exhibit profound differences in the intestinal metabolome, including 
lower concentration of short chain fatty  acids10,11, higher concentration of amino  acids11, and a dysregulation of 
bile acid composition, including higher conjugated and lower secondary bile acid  concentrations12.
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EEN therapy likely modulates both the microbial and metabolic environments in the gut of patients with 
 CD13–15. Several studies demonstrated that EEN reduces the alpha diversity of the intestinal microbiota of patients 
with  CD14,15. This appears paradoxical, as higher alpha diversity is often associated with a more “healthy” micro-
biota. More specifically, EEN was found to induce a decline in numbers of presumably protective gut bacterial 
species (e.g. Faecalibacterium prausnitzii and Bifidobacterium spp.). In addition, decreased concentrations of fecal 
short chain fatty acids (SCFAs) such as butyrate, which is generally thought to be a beneficial metabolite for host 
health, have been found to be associated with disease improvement during  EEN15. However, from a nutritional 
and microbiological point of view, these findings are to some extent expected. Because EEN contains relatively 
few components, when compared to a regular diet, a reduced alpha diversity of the gut microbiota is likely to 
result in people with this diet. In addition, removing complex carbohydrates from the diet reduces the amount 
of substrate available for fermentation into SCFAs by fiber-degrading bacterial taxa.
Whether changes in the intestinal microbiota and metabolome are a cause or consequence of CD remains 
uncertain, primarily due to the lack of longitudinal  observations8,16. Two recent papers show that diets with 
either partial  EEN17 or mimicking EEN composition with more solid  ingredients18, are equally effective as 
EEN in inducing remission in patients with pediatric CD. These  papers17,18 are important because the novel 
nutritional therapies are better tolerated and would thus be beneficial for a larger number of patients. Moreover, 
these  papers17,18 also show that changes in the fecal microbiota and metabolome induced by these novel nutri-
tional therapies are comparable to the changes that are induced by EEN. The findings reported thus also provide 
evidence that changes in the microbiota and metabolome could be causative in inducing remission in patients 
with pediatric CD disease.
In this study we prospectively followed a cohort of pediatric treatment-naïve patients with CD undergoing 
EEN therapy and investigated changes in their fecal microbiota and metabolome. The aims of this study were; 
(1) to describe gut microbial and metabolic changes during the course of EEN and the differences between 
responders and non-responders to EEN. (2) To evaluate these microbial and metabolic changes as potential 
mechanisms of EEN action.
Results
Patients. In total, 43 children with newly diagnosed CD were included (47% male, median age, 14 years 
[IQR 12–15], Fig. 1A,B). Patient and disease characteristics, and clinical and biochemical response are shown 
in Fig. 1B and Table 1 and were partially described  previously19. In addition to EEN, all patients were started 
on concomitant thiopurines (i.e. azathioprine) following the international  guidelines1. Eighteen healthy con-
trols participated (50% male, median age years 13 [IQR 11–16]). For the microbiota analysis 96 samples were 
included, at baseline (T0) 27 samples, during EEN (T1) 22 samples, at end of EEN (T2) 19 samples, at follow up 
on habitual diet (T3) 13 samples, and 15 healthy control samples. For the metabolite analysis 122 samples were 
included, at baseline (T0) 43 samples, during EEN (T1) 37 samples, at end of EEN (T2) 22 samples, at habitual 
diet (T3) 20 samples, and 31 healthy control samples were included. 
Some patients halted EEN due to various reasons. The samples of these patients were analyzed up to the latest 
time point at which they did receive EEN and were excluded from further study.
Regarding control samples used in this study; two time points of the 18 control subjects were analyzed in the 
metabolic analysis. Five samples had to be excluded because of preparation errors. For the microbiome analysis 
only 15 controls at a single time point were used because of limitations in sequence capacity. The overall study 
design is shown in Fig. 1A,B.
Responders to EEN were identified by a reduction of fecal calprotectin of more than 50% at T2, compared to 
T0. See Fig. 1B and Table 1 for patient inclusions. Pilot analysis did not reveal statistically significant correlations 
when using the clinical definitions for remission (data not shown).
Microbiota. Healthy controls versus patients with CD. To investigate the fecal microbiota of patients with 
CD and controls and the effect of EEN treatment, 16S rRNA gene amplicon sequence analysis was carried out.
At baseline, patients had reduced observed OTU richness, as compared to healthy controls (HC, mean OTU 
richness of 235.6 vs. CD T0, mean OTU richness of 192.9, p = 0.036, Mann–Whitney, Fig. 2A). Shannon and 
inverse Simpson diversity measures, which incorporate species evenness as well as richness, were not significantly 
different between controls and patients at baseline (HC 3.67 vs. T0 3.4, p = 0.098, and HC 20.37 vs. CD T0 16.75, 
p = 0.198, respectively).
As expected, the overall microbial composition of controls was highly different (p < 0.001) from that of 
patients at all time points (Bray Curtis with AMOVA, Table 2, Fig. 2E). Numerous taxa exhibited significantly 
different proportional abundances; Escherichia coli, Ruminococcus gnavus, Dorea longicatena, and Blautia spp. 
were present in greater relative abundance in CD, whereas Eubacterium rectale, Bifidobacterium longum and 
Ruminococcus bromii were proportionally higher in controls (all p values < 0.05 with both LEfSe and Benja-
mini–Hochberg-corrected p values generated by Metastats) Supplementary Table 4 details the differences of the 
most proportionally abundant species between patients with CD at T0 and controls.
The effect of EEN on the microbiota. EEN therapy caused a decrease in microbial diversity, with patients at T1 
and T2 having a significantly lower diversity than at baseline (mean inverse Simpson Index score for T0 = 19.40 
vs. T1 = 11.57, p = 0.003) (T0 = 19.40 vs. T2 = 12.85, p = 0.045) (Fig. 2B). At follow up (T3) there was no difference 
in diversity from baseline (mean T0 inverse Simpson index score = 19.40 vs. T3 mean = 16.87, p = 0.505).
The introduction of EEN was also significantly associated with a shift in the overall microbial composition 
(T0 vs. T1, p =  < 0.001) and at the end of EEN (T0 vs. T2, p =  < 0.001), with differences disappearing at follow up 
(T0 vs. T3, p = 0.99) (Bray Curtis-based AMOVA tests, Table 2). However, the response of individual taxa varied 
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greatly between individuals. (Supplementary Figure 1). Only genera that were identified as being significantly 
different using the stringent, Benjamini–Hochberg-corrected, Metastats-based approach, and with a proportional 
abundance of more than 0.01% of the total observed microbiota, are detailed below. The genera significantly 
altered between baseline (T0) and during the EEN treatment (T1) were Blautia (10.8% of the total observed 
microbiota across all samples) and Subdoligranulum (2.5% of the total observed microbiota), both of which 
were reduced in relative abundance during EEN therapy, (Metastats-based p = 0.033 and p = 0.044, respectively) 
(Fig. 2C,D). However, neither of these genera was significantly reduced at timepoint T2 compared to T0. No 
bacterial taxa were shown to be significantly increased in proportional abundance with both the Metastats-based 
and LEfSe approaches as a result of the EEN therapy.
Responders versus non‑responders. Prior to the onset of EEN therapy, the overall composition of the microbiota 
differed between subsequent responders and non-responders (Bray Curtis dissimilarity analysis and AMOVA 
tests, p = 0.008). A PCoA plot is shown in Fig. 2F.
Due to the high inter-individual variation in microbiota composition, there were no significant differences 
in alpha diversity measures, and few species or genera that differed between responders and non-responders 
prior to therapy (T0). However, Dorea longicatena (2.5% of the total observed microbiota) (Metastats-based 
p = 0.012; LEfSe p = 0.005), (Fig. 2G) Blautia obeum (1.3% of the total observed microbiota) (Metastats-based 
Figure 1.  Study outline and patient selection. Panel (A) shows the therapy and time points of fecal sample 
collection. In panel (B) the selection of patients that were included in this study is outlined.
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p = 0.019; LEfSe p = 0.006) (Fig. 2H), and Bifidobacterium longum (0.07% of the total observed microbiota) 
(Metastats-based p = 0.040; LEfSe p = 0.012) (Fig. 2I) were all associated with lack of response. Using three-way 
LEfSe analysis, comparing healthy controls versus responders (T0) versus non-responders (T0), multiple taxa 
appeared to be associated with both responders and non-responders at T0. Supplementary Table 5a details the 
most important differences between healthy controls, responders and non-responders at T0. The following 
taxa are examples of proportionally abundant components of the bacterial “signature” that differentiated non-
responders from responders prior to therapy (T0): Dorea longicatena (Non-responders, p =  < 0.001), Blautia 
obeum (Non-responders, p = 0.002), and Escherichia coli (Non-responders, p =  < 0.001).
At the follow up period (T3), there were also differences between responders and non-responders. As with T0, 
the overall composition of the microbiota at T3 also differed between responders and non-responders (Bray Cur-
tis dissimilarity analysis and AMOVA tests, p = 0.004). (PCoA plot shown in Supplementary Figure 3A). Of note, 
both Metastats-based and LEfSe analyses associated higher proportional abundances of the butyrate-producing 
genus Roseburia with responders (2.40% mean proportional abundance at T3 in responders vs. mean of 0.22% 
in non-responders, Benjamini–Hochberg-corrected Metastats-based p = 0.043, LEfSe p = 0.013), while another 
key butyrate-producing genus, Faecalibacterium, was also associated with responders by LEfSe only (10.48% 
mean proportional abundance in responders vs. mean of 1.42% in non-responders, p = 0.041). Three-way LEfSe 
analysis, comparing healthy controls versus responders (T3) versus non-responders (T3), associated, amongst 
others, Faecalibacterium prausnitzii (p = 0.034), Bifidobacterium adolescentis (p = 0.032), and Ruminococcus bromii 
(p = 0.009) with responders, and Escherichia coli (p = 0.004) and four Blautia OTUs (p = 0.003, 0.008, 0.026, and 
0.009) with non-responders.
Supplementary Table 5b details the most important differences between healthy controls, responders and 
non-responders at T0 and at T3.
Thus, EEN significantly changes both alpha and beta diversity indices in patients with CD, and we provide 
evidence for differences between responders and non-responders both prior to and after therapy.
1H NMR spectroscopy-based metabolic profiling analysis. Healthy controls versus patients with 
CD. Metabolic differences between patients with CD and controls and the effects of EEN were analyzed using 
1H NMR spectroscopy.
Significant differences were observed between patients with CD and HC at all time points based on Orthogo-
nal Partial Least Squares-Discriminant Analysis (OPLS-DA) models. An example of the cross-validated scores 
plot of OPLS-DA between the HC and patients with CD at T0 is shown in Fig. 3A  (R2X = 59.7%,  Q2Y = 0.55, 
permutation p = 0.01). The corresponding ROC curve (Supplementary Figure 2A, AUC = 0.94) confirms that this 
model is highly predictive to distinguish patients from controls. Amino acids (alanine, tryptophan, tyrosine, 
valine, isoleucine, leucine, phenylalanine) and microbial metabolites (cadaverine, lactate, propionate, putrescine, 
trimethylamine (TMA)) were found in higher concentrations in patients with CD at T0 compared to healthy 
controls (Supplementary Table 6).
The effect of EEN on the metabolome. EEN affected the global metabolome with the fecal metabolic profile prior 
to EEN (T0) differing significantly from the end of EEN (T2)  (R2X = 59.4%,  Q2Y = 0.1, p = 0.04, Fig. 3B). How-
ever, the corresponding ROC curve (Supplementary Figure 2B, AUC 0.71) does not suggest a highly predictive 
value of the model at this time point. No significant differences were found between other time points.
Responders versus non‑responders. When patients were stratified based on their responses to EEN therapy, there 
was a statistically significant difference between the fecal metabolic profiles of responders and non-responders at 
Table 1.  Patient characteristics of included CD patients. CD Crohn’s disease. a L1: distal 1/3 ileum ± limited 
cecal disease; L2: colonic; L3: ileocolonic; L4a: upper disease proximal to the ligament of Treitz; L4b: upper 
disease distal to ligament of Treitz and proximal to distal 1/3 ileum.
Total Crohn’s disease patients (n = 43)
Microbiota analysis (n = 27) Metabolite analysis (n = 43)
Age (median, IQR) 14 (12–15) 14 (12–15)
Males 14 (52%) 20 (47%)
Crohn’s disease: age at diagnosis (Paris classification)
A1a: 0– < 10 years 3 (11%) 4 (9%)
A1b: 10– < 17 years 24 (89%) 39 (91%)
Crohn’s disease: locationa (Paris classification)
L1: distal 1/3 ileum 2 (7%) 5 (12%)
L2: colonic 2 (7%) 9 (21%)
L3: ileocolonic 23 (85%) 29 (67%)
Clinical responders 17 (63%) 28 (65%)
Biochemical responders that completed EEN 6 (38%) (total n = 16) 10 (45%) (total n = 22)
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Figure 2.  Microbiota of patients versus controls, the effect of EEN and differences between responders and 
non-responders. Panel (A) shows the difference in richness between controls and patients at T0. Panel (B) shows 
that EEN reduced diversity. Panel (C) and (D) show the effect of EEN on the proportional abundance of the 
Blautia and Subdoligranulum genera. Principal coordinate (PCoA) plots in panels (E) and (F) show separation 
of controls (red) and patients (blue), and responders (red) and non-responders (blue) at T0. In panels (G,H) and 
(I) some of the species that comprise the signature of responders versus non-responders at T0 are depicted. HC 
healthy controls, R responders, NR non-responders.
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baseline (T0)  (R2 = 60.4%,  Q2 = 0.28, p = 0.030, Fig. 3C). The ROC curve (Supplementary Figure 2C, AUC = 0.8) 
suggests that the fecal metabolic profiles could predict the responses of patients to EEN prior to the treatment.
Although the global metabolic profiles of both responders  (R2X = 58.0%,  Q2Y = 0.33, p = 0.01) and non-
responders  (R2X = 67.5%,  Q2Y = 0.69, p = 0.01) were different from healthy controls at follow-up (T3), several 
metabolites (i.e. leucine, propionate, valine, lactate, alanine, cadaverine, trimethylamine, tyrosine, phenylalanine, 
isovalerate, urocanate, succinate) were normalized in responders but not in non-responders (Supplementary 
Table 6).
Amino acids. Healthy controls versus patients with CD. Because the NMR analysis showed large differences 
in amino acids between patients with CD and controls, we investigated fecal amino acids in more detail using 
HPLC. At baseline (T0), there was a clear separation of the fecal amino acid profile in CD from HC, with a higher 
concentration of the total and most individual amino acids (Fig. 3D, Supplementary Table 7, Supplementary 
Table 8). Only glutamic acid, arginine and taurine were not elevated in patients.
The effect of EEN on amino acids. Total amino acid concentrations tended to decrease at T1 when compared 
to T0. However, the fecal amino acid profiles at baseline (T0) were not significantly different from time-points 
(T1, T2 & T3), for either the total or individual amino acid concentrations (Fig. 3D, Supplementary Table 7, 
Supplementary Table 8).
Responders versus non‑responders. When patients were stratified based on response to EEN therapy, respond-
ers had a lower fecal concentration of histidine, citrulline, and isoleucine both at baseline (T0) and at the end of 
EEN therapy (T2), and a lower concentration of serine, glycine, and alanine at end of EEN therapy (T2) (Sup-
plementary Table 9).
We also compared amino acids between healthy controls, responders and non-responders. Although some 
individual amino acids of both responders and non-responders had a higher concentration in healthy controls 
at follow-up (T3) (i.e. asparagine, tryptophan), many amino acid concentrations were normalized in responders 
and not in non-responders at T3 (i.e. serine, histidine, tyrosine, phenylalanine, leucine), (Supplementary Table 8).
CD does not affect systemic amino acids. To establish whether the elevated fecal amino acids in patients with 
CD are reflected in the systemic circulation we measured plasma amino acids in an independent cohort of 
pediatric IBD patients (N = 41, 63% male, median age 15 years [IQR 12–16], median disease duration 22 months 
[IQR 10–44], 76% CD, 24% ulcerative colitis). No correlation was found between plasma total, or individual 
amino acids concentrations and disease severity as measured by fecal calprotectin (r: 0.166, p = 0.306, Supple-
mentary Figure 3B).
Bile acids. Healthy controls versus patients with CD. Bile salts are emerging as important mediators in im-
mune  function20. Because little is known about bile salt metabolism in CD and during EEN, we analyzed the 
fecal bile acid composition by HPLC. Although the total concentrations of bile acids were not different between 
patients with CD and controls (Fig. 3E, Supplementary Table 10), the metabolism of fecal bile acids was sig-
nificantly changed in patients with CD (Fig. 3F, Supplementary Figure 3D–H). At baseline (T0), the relative 
concentration of primary bile acids was higher in patients with CD resulting in a reduced hydrophobicity of the 
bile acid pool (Fig. 3G, Supplementary Table 10).
Table 2.  Differences in overall bacterial community composition between controls (HC) and patients at 
T0, and between patients during EEN. Controls were different from patients at all time points. EEN induces 
significant changes in microbial composition, T0 versus T1 and T2. At follow up T3, microbial composition 
of patients was not different from that at the start, T0. Differences in community composition were analyzed 
using the AMOVA test in mothur, using Bray Curtis dissimilarity measures.
p
HC versus T0  < 0.001*
HC versus T1  < 0.001*
HC versus T2  < 0.001*
HC versus T3  < 0.001*
T0 versus T1 0.001*
T0 versus T2 0.001*
T0 versus T3 0.9999
T1 versus T2 1.000
T1 versus T3 0.025*
T2 versus T3 0.093
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The effect of EEN on bile acids. Comparing the fecal bile acids at baseline (T0) to during EEN (T1), or time-
points after EEN cessation (T2 & T3), revealed no difference in bile acids hydrophobicity or the percentage of 
secondary bile acids (Fig. 3G, Supplementary Table 11).
Responders versus non‑responders. When patients were stratified based on response to EEN therapy, there was 
no difference in the total bile acid concentration, bile acid hydrophobicity and the fraction of secondary bile 
acids between responders and non-responders at baseline (T0), or other time points (T1-3) (Supplementary 
Tables 10 and 11).
At follow-up (T3), the fraction of secondary bile acids and the total bile acid concentration in feces of respond-
ers and non-responders did not differ from HC (Supplementary Table 10). However, bile acid hydrophobicity 
was normalized in responders and not in non-responders at follow-up (T3) (Supplementary Table 10).
Figure 3.  Differences in fecal metabolites between patients and controls, responders and non-responders 
and the effect of EEN on the fecal metabolome. Panels (A–C) show OPLS-DA plots. This analysis indicates 
that 1HNMR analysis can distinguish controls (blue) from patients (red) at T0, panel (A). A marginal EEN 
induced change in metabolome from T0 (red) to T2 (blue) is shown in panel (B). The difference in metabolome 
between responders (blue) and non-responders (red) at T0 is shown in panel (C). Panel (D) shows increased 
total fecal amino acids in patients that decrease during EEN therapy. Panel (E) shows that bile salts are not 
elevated in patients and unchanged during therapy. Panels (F) and (G) show decreased bile salt metabolism and 
hydrophobicity in patients at T0 that is partially normalized during therapy. Panels (H) and (I) show increased 
levels of trimethylamine and cadaverine respectively and show partial normalization of these compounds during 
EEN therapy. HC healthy controls, R responders, NR non-responders.
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Effects of selected metabolites on physiological parameters. After establishing the effect of EEN 
on fecal metabolic composition we investigated if metabolites that were shown to be different between controls 
and patients with CD could have a causal role in disease development.
TMA and cadaverine inhibit Caco‑2 proliferation. Since wound healing is a critical process in recovery from 
inflammation we used a real time assay of cell growth and attachment to study the effect of selected metabolites 
on this process.
TMA and cadaverine were metabolites of interest as they differed between patients with CD and healthy 
controls and are metabolic products of intestinal microbes (Fig. 3H,I)21,22,23. These compounds were especially 
interesting because they were normalized in responders only at follow up (Supplementary Table 6). As a con-
trol metabolite for TMA we selected TMA N-oxide (TMAO), which is produced from TMA by hepatic flavin 
monooxygenases 3 (FMO3)24.
Both TMA and cadaverine inhibited caco-2 cell proliferation, relative to standard DMEM medium (Fig. 4A,B, 
Table 3). The control metabolite TMAO, did not inhibit caco-2 cell proliferation (Fig. 4A, Table 3).
TMA and cadaverine reduce LPS induced TNFα and IL‑6 secretion in primary human lymphocytes. A possible 
mechanism by which microbial metabolites induce remission is by modulating the host immune response. We 
Figure 4.  The effect of TMA and cadaverine on cell growth, differentiation and cytokine secretion. Panel 
(A) shows that TMA, but not its metabolite TMAO reduces  CaCo2 cell growth in a concentration dependent 
manner. Panel (B) shows that cadaverine reduced  CaCo2 cell growth in a concentration dependent manner. 
Panels (C) and (D) show that TMA, but not its metabolite TMAO, and cadaverine are both able to reduce LPS 
induced TNFα and IL-β secretion in primary human PBMC.
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therefore studied the effect of selected metabolites on LPS induced cytokine secretion in primary human lym-
phocytes.
Human peripheral blood monocytes were incubated with TMA, TMAO and cadaverine for 24 h and sub-
sequently stimulated with LPS. IL-6 and TNFα release from primary human monocytes upon LPS stimulation 
was inhibited by TMA and cadaverine but not by TMAO (Fig. 4C,D), p < 0.0001. The differences in IL-6 and 
TNFα release by monocytes were not caused by increased cell death as shown by FACS viability staining (Sup-
plementary Figure 3C).
Amino acid feeding worsens outcome of a mouse model of intestinal inflammation. Since amino acids were ele-
vated in patients, and many amino acids were normalized in responders at T3 only (Supplementary Table 9) we 
wanted to investigate a causal role of these compounds in inflammation. As cell culture models are not suitable 
for studying the effect of amino acids, we determined if these compounds could affect the DSS model of intes-
tinal inflammation.
Mice were fed amino acids or a diet containing a caloric equivalent amount of whole milk protein. Non-DSS 
treated mice fed with standard chow served as a control group. Weight loss, stool score, pathology, and endoscopy 
score were all worse in DSS treated mice (both amino acid or milk protein fed) compared to the control group 
(Fig. 5A–D). Amino acid-fed DSS mice had a lower body weight, and significantly (p < 0.0001) worse pathology 
and endoscopy score compared to milk-protein fed DSS mice (Fig. 5A–D).
TNF-α expression was higher in the colons of DSS treated mice (both amino acid or milk protein fed) com-
pared to control mice (Fig. 5E), IL-6 was only higher in the colons of DSS-treated mice fed with amino acids 
(Fig. 5F). Amino acid-fed mice showed a significantly (p = 0.028) increased expression of IL-6 over those fed with 
milk protein (Fig. 5F). TNF-α, did not show differences between amino acid and milk protein fed mice (Fig. 5E).
Discussion
In this study, we report a comprehensive analysis of the fecal microbiota and metabolome during a course of 
EEN therapy in patients with CD.
Microbiota analysis. We found marked differences in microbiota between patients with CD and controls. 
The differences, as seen in this cohort, largely correspond to previous  studies25–28.
The microbiota of children with CD was highly variable, as has been reported  before13. Nonetheless, patients 
with CD had a reduced richness as compared to controls prior to therapy. In common with many  studies29,30, we 
also detected increased proportional representation of Escherichia coli and Ruminococcus gnavus31 in patients 
with CD, and a reduction in the relative abundance of putatively beneficial organisms such as Bifidobacterium 
spp., and butyrate producers such as E. rectale. During EEN, diversity (as measured using the inverse Simpson 
Index) was further reduced, confirming results from a previous  study14.
Although limited by our relatively small number of samples, our results suggest that increased proportional 
abundance of taxa such as Bifidobacterium longum, Dorea longicatena, and Blautia obeum may indicate a lower 
chance of disease remission following EEN. Our observations suggest that the Blautia genus is of particular 
interest since proportional abundances of this group were generally higher in patients with CD versus healthy 
controls at baseline, were reduced in patients with CD during the EEN period, and were associated with non-
responders at both T0 and T3. In contrast, a randomized clinical trial comparing nutritional interventions in 
pediatric patients with CD reported an increase in the Blautia genus during  EEN17.
A meta-analysis of microbiota profiling studies in adult IBD patients reported an association of increased 
proportional abundance of Blautia spp. in patients with  CD32. A more recent study showed that Blautia spp were 
associated with a dysbiotic cluster that separated part of patients with pediatric CD from  controls33 Another study 
in pediatric CD reported increased Blautia, comparable to controls in patients with sustained response to Inflixi-
mab  treatment34. Observations on Blautia spp from individual studies of pediatric CD cohorts thus appear to be 
variable, possibly because the resolution of genus level comparisons is not sufficient and masking contributions 
Table 3.  The effect of the metabolites TMA and cadaverine on epithelial cell proliferation and adhesion (cell 
index). Cell index was measured on  CaCo2 cells using a real time assay. TMA and cadaverine significantly 
inhibited proliferation and adhesion at all concentrations tested compared to controls. Cell indices were 
compared using the Mann–Whitney U test.
p: 24 h p: 48 h p: 72 h
TMA versus control
TMA 1.0 mM versus control (DMEM)  < 0.001  < 0.001 0.021
TMA 5.0 mM versus control (DMEM)  < 0.001  < 0.001  < 0.001
TMA versus TMAO
TMA 1.0 mM versus TMAO 1.0 mM 0.001 0.004 0.010
TMA 5.0 mM versus TMAO 5.0 mM  < 0.001  < 0.001  < 0.001
Cadaverine versus control
Cadaverine 1.0 mM versus control (DMEM)  < 0.001  < 0.001  < 0.001
Cadaverine 10.0 mM versus control (DMEM)  < 0.001  < 0.001  < 0.001
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Figure 5.  A diet of amino acids worsens the murine DSS model of colitis. Mice received 1.5% DSS in their 
drinking water and were fed chow supplemented with milk protein (DSS milk protein) or an equivalent amount 
of amino acids (DSS Amino Acids). Control mice received milk protein (No DSS milk protein). Mice fed amino 
acids lost weight more rapidly (panel A), had increased stool, pathology and endoscopy scores, (panels B–D). 
Levels of TNFα, as measured by quantitative PCR, were elevated in both groups (panel E) whereas levels of IL-6, 
as measured by quantitative PCR, were only elevated in the group receiving amino acids (panels F).
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of Blautia species, or because the inherent inter-individual variation in microbiota composition makes it more 
difficult to find reproducible findings across different cohorts. More mechanistic research is evidently required 
in future in order to determine whether or not these species are playing a role in the disease process.
Metabolites. In contrast to the microbiota, the metabolome trended towards normalization for many com-
pounds as a result of EEN therapy. These observations are not completely surprising as the diversity measures 
used in this study reflects microbiota composition and not its metabolic activity.
Several microbial metabolites that could play a role in the pathogenesis of CD were identified in this study. 
Cadaverine and trimethylamine (TMA) were found in a higher concentration in patients with CD, tended to 
decrease during the course of EEN (Fig. 3H,I) and were normalized at T3 in responders only.
Increased amino acids have been previously observed in CD  patients35–37. The most straightforward expla-
nation for this phenomenon is a reduced uptake due to a damaged epithelium. However, because total bile salt 
concentrations were not different between patients with CD and controls, and glutamic acid and taurine levels 
were not elevated in patients with CD, reduced epithelial uptake capacity does not seem a likely explanation for 
increased amino acid levels.
Mechanism of EEN. A possible causal role of elevated amino acids in CD is suggested by our observations 
that a diet containing amino acids worsens DSS induced colitis in a mouse model. These results are surprising 
in the light of previous studies showing that supplementation of amino acids reduces DSS-induced  colitis38,39.
As examples, supplementation of mice in de DSS model of colitis with dietary  tryptophan40,  glutamine41, 
 serine42 or  arginine43 reduced inflammation.
However, study designs are not completely comparable, since we fed mice a complete mixture of amino acids 
compared to supplementation with selected amino acids. A recent paper shows that elevated fecal amino acids in 
patients with CD depended on increased urease activity of the  microbiota37. Inoculation of a murine colitis model 
with E. coli engineered to express urease led to a worsening of the colitis in these animals. Increased amounts of 
amino acids seen in patients with CD might thus have a role in pathogenesis.
Cadaverine and TMA inhibit epithelial growth and adherence. This indicates that high levels of TMA and 
cadaverine could be detrimental for gut homeostasis and that these metabolites may be important in CD patho-
genesis. Decreased serum levels of TMAO have been observed in patients with inflammatory bowel disease, 
providing additional evidence that reduced TMA metabolism might play a role in CD  pathogenesis44.
Perhaps surprisingly, TNFα and IL-6 production of LPS stimulated human monocytes was reduced by TMA 
and cadaverine. However, besides its role as a pro-inflammatory cytokine, multiple anti-inflammatory effects of 
TNFα have also been  described45–47.
Our data from the DSS model of colitis also suggest a complex role of TNFα and IL-6 in intestinal inflam-
mation. Whereas amino acid feeding increased severity of intestinal inflammation, as assessed by multiple 
parameters, it only increased IL-6 levels, TNFα levels were unchanged.
Short chain fatty acids (SCFA) have been extensively studied in patients with  IBD48. In this cohort, propionate 
concentrations were higher in children with CD, while butyrate levels were unaltered (not shown). Data regarding 
the effect of EEN on SCFA levels are conflicting, with decreases and increases both  observed15,49.
The fecal bile acid pool of patients with CD was characterized by a higher concentration of primary and 
conjugated bile acids and lower secondary bile acids. This likely results in a fecal bile salt pool that is less hydro-
phobic in patients with CD. During EEN therapy, this alteration in bile acid composition was partially restored 
(Supplementary Figures 3D–H). Our results expand on an earlier  study12, that showed similar alterations of the 
CD gut bile acids.
The anti-inflammatory effects of the TGR5 bile acid receptor activation are well  described48. Since hydro-
phobic bile acids such as lithocholic acid are more potent activators of TGR5 than the hydrophilic bile  acids50, 
the hydrophilic bile salt pool of patients with CD could be an important factor in the inflammatory process.
Differentiating responders and non-responders prior to therapy. Fecal microbiota and metabo-
lome of responders and non-responders differ before the start of EEN therapy. Microbial differences between 
responders and non-responders to immunomodulators or nutrition have been reported  before51,52. This could 
indicate that there might be as yet unidentified subtypes of CD disease and open the possibility to identify non-
responders before treatment. This approach seems feasible as a recent  paper53 identifies microbial signatures that 
could predict long term responders to EEN.
Conclusions. Patients responding to EEN therapy have different microbiota and metabolomes prior to ther-
apy than patients that do not respond. This may allow for future prediction of EEN response.
The mechanism by which EEN induces remission is complex, several metabolites (TMA, cadaverine, amino 
acids and bile salts) possibly have a causal role in the development of CD.
Patients, materials and methods
Ethics. The Medical Ethical Committee of the Amsterdam UMC (Medisch Ethische Toetsingscommissie) 
approved the analysis of human samples described in this study under NL39254.029.12. In accordance with 
this approval, the children and their parents both gave informed consent for the use of pediatric samples in this 
study. All analysis and further experiments in this study were performed according to this approved protocol 
and relevant regulations and guidelines.
Animal experiments described in this study were performed according to a protocol that was approved by 
the Animal Ethical Committee of the Amsterdam UMC, (Dierexperimentele commissie) under nr DMO65. All 
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analysis and further experiments in this study were performed according to this approved protocol and relevant 
regulations and guidelines.
Patients. This was a prospective multi-center cohort study in two academic hospitals (Amsterdam UMC 
locations AMC and VUMC) performed between January 2010 and July 2014. All children (< 18 years) with 
newly diagnosed, therapy naïve CD according to the revised Porto  criteria54 undergoing EEN induction treat-
ment were included. The control group consisted of age and sex matched, healthy school children from the 
same geographic area, with no family history of inflammatory bowel disease (IBD), from a well-documented 
 cohort55. An outline of analysis performed in this study can be found in Fig. 1A,B). Participants who received 
antibiotics or probiotics within 3 months prior to inclusion or during the study period were excluded. Moreover, 
participants with a proven bacterial gastroenteritis or who had taken immunomodulatory drugs 3 months prior 
to inclusion were also excluded. A range of polymeric EEN formulas with similar composition based on cow 
milk protein (Supplementary Table 1) was provided during a 6-week course, during which no other food or fluid 
(except water) was allowed, followed by a 2-week course of EEN tapering and gradual introduction of habitual 
diet. During follow-up, dose adjustments or switch of maintenance therapy (and reasons for therapy adjustment) 
were collected. Localization and disease behavior were classified using the Paris  classification56.
Sample collection. Patient and healthy controls were instructed to collect fecal samples in provided sterile 
containers, to store the sample at − 20 °C within at least 2 h of collection, and to deliver these frozen samples 
in a cooled condition to the hospital. A maximum of 4 samples were collected per patient at the following time 
points: At the time of diagnosis, but prior to bowel preparation and endoscopy (T0), during EEN (± 21 days after 
EEN initiation) (T1), at the end of treatment (± 42 days after EEN initiation) (T2), and after patients returned 
to their habitual diet (± 4 months after EEN initiation) (T3) (Fig. 1A). To avoid heterogeneity, samples from 
patients who had discontinued EEN therapy prematurely were excluded: T1 samples were excluded if EEN was 
previously discontinued, T2 and T3 samples were excluded if the full course of 6 weeks EEN had not been com-
pleted. Healthy controls were instructed to collect 2 fecal samples with an interval of 6 weeks. Aliquots of fecal 
samples were stored at − 20 °C until analysis.
Biochemical and clinical disease activity. Biochemical disease activity was assessed using fecal calpro-
tectin (FC), the most accurate fecal biomarker of intestinal inflammation currently  available57. Fecal calprotectin 
levels were determined at baseline (T0) and end of EEN (T2) by the Amsterdam University Medical Centre 
hospital clinical chemistry laboratory. Biochemical response was defined as a reduction of ≥ 50% at T2 compared 
to T0, as this has the highest predictive value for endoscopic treatment  response58. Because we did not obtain 
calprotectin from all patients and not all patients completed EEN therapy, for the analysis of responders versus 
non-responders not all samples could be used.
Clinical disease activity was assessed by the treating physician at T0 and T2 using the Physician Global 
Assessment (PGA) 4 point scale: inactive, mild, moderate, and  severe59. Clinical response on EEN was defined 
as a PGA scored as inactive to mild after a full 6 week-course of EEN, without the need for additional remission 
induction treatment.
Microbiota analysis using 16S rRNA gene amplicon sequencing. Sequencing of bacterial 16S 
rRNA gene amplicons was performed to characterize microbial community composition, largely as described 
 in60, of which a modified version is described below.
DNA extraction. DNA extraction was carried out on fecal samples, ranging from 25 to 265 mg in weight, using 
the FastDNA SPIN Kit for Soil (116560200, MP Biomedicals) per kit instructions. Samples were eluted in 50 µl 
of DES then quality checked by running on an agarose gel.
PCR amplification for sequencing. PCR amplification of the V1-V2 hypervariable regions of the 16S rRNA 
gene was carried out using primers adapted for Illumina MiSeq, 27F (AAT GAT ACG GCG ACC ACC GAG ATC 
TAC-ACT ATG GTA ATT CCA GGT TYG ATY MTGG CTC AG) and 338R individually barcoded (CAA GCA GAA 
GAC GGC ATA CGA GAT -barcode-AGT CAG TCA GAA GCT GCC TCC CGT AGG AGT ) primers. 1 µl of extracted 
DNA was run in a 25 µl PCR reaction containing 1.25 µl of each primer (10 µM), 5 µl of 5X Q5 Reaction Buffer, 
0.25 µl of Q5 High-Fidelity DNA Polymerase (M0491, New England Biolabs), 0.5 µl of 10 mM dNTPs (N0447, 
New England Biolabs) and 15.75 µl of Nuclease-Free water as per Q5 standard protocol. Four PCR reactions 
were run for each sample using thermal cycler conditions of 98 °C for 2 min, then 20 cycles of 98 °C for 30 secs, 
50 °C for 30 secs, 72 °C for 90 secs before a final extension of 72 °C for 5 min. Sample reactions were pooled 
and checked by running on an agarose gel before being cleaned by ethanol precipitation then quantified using 
the Qubit dsDNA HS Assay Kit (Q32854, Invitrogen/Life Technologies). An equimolar mix of all samples was 
prepared before carrying out a final clean up step using the Wizard SV Gel and PCR Clean-Up System (A9281, 
Promega). The equimolar mix was then eluted in 50 µl of Nuclease-Free Water, of which 25 µl was submitted for 
Illumina MiSeq sequencing (paired end 250 bp read length) at the Wellcome Sanger Institute in Cambridgeshire, 
UK.
Analysis of microbiota sequence data. Illumina MiSeq data was analyzed using mothur software (v 1.39.5)61, 
similar to as described by Dalby et al.60. Contigs were assembled using the forward and reverse reads, and only 
those which were between 280 and 470 bases were taken forward in the analysis pipeline. Sequences were aligned 
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against the SILVA reference database and operational taxonomic units (OTUs) generated (97% similarity) using 
the default OptiClust option in  mothur62. Representative sequences were obtained for each OTU and these were 
then able to be run through the BLAST database for species identification. Unlike Dalby et al.  201760, no chimera 
removal software was used and instead a cut-off to remove all sequences with 10 reads or less applied. All sam-
ples were sub-sampled to 4237 reads to allow comparison across all samples at the same depth of coverage. The 
median Good’s coverage estimate at this sequence depth was 98.07% (range from 96.55 to 99.74%). Sequence 
data have been deposited in the European Nucleotide Archive under study accession number PRJEB14084. The 
final OTU table of the 500 most abundant OTU is shown as Supplementary Table 2, alongside results for each 
sample at the genus, family and phylum levels. Principal Coordinate Analysis (PCoA) plots, and dendrograms 
were created from the OTU-level data using the Bray Curtis dissimilarity calculator in  mothur62.
Quantitative reverse transcriptase-PCR. RNA was isolated using an Isolate II RNA micro kit (Bioline). 
cDNA was synthesized by means Superscript II reverse transcriptase (Invitrogen) for colon with oligo (dT) and 
random primers. A SYBR green-based real-time PCR technique was used to detect the expression of transcripts 
(SensiFAST master mix, GC-Biotech). Real-time PCR was performed using the Light cycler 480 (Roche) detec-
tion system. Data were analyzed using LinregPCR  software63 and results were expressed as fold difference rela-
tive to the geometric mean expression of the reference genes ubiquitin and cyclophilin for murine colon. The 
following human primers sets were used:
β-actin F: AAT GTG GCC GAG GAC TTT GA, R: TGG CTT TTA GGA TGG CAA GG, GAPDH F: GAG TCA ACG 
GAT TTG GTC GT, R: TTG ATT TTG GAG GGA TCT CG, mTNF F: TGG AAC TGG CAG AAG AGG CACT, R: CCA 
TAG AAC TGA TGA GAG GGA GGC , mIL-6 F: AGT TGC CTT CTT GGG ACT GA, R: TCC ACG ATT TCC CAG AGA 
AC, mIL-1b F: GCC CAT CCT CTG TGA CTC AT, R: AGG CCA CAG GTA TTT TGT CG.
Metabolome analysis. 1H Nuclear magnetic resonance (NMR) spectroscopy. Fecal samples were weighted 
and mixed with water (UPLC grade) in a ratio of 1 mg : 4 μl (fecal weight : water volume). The samples were 
mixed by pipetting, vortexing and centrifuged at 18,000g for 10 min at 4 °C. The fecal water supernatant was then 
separated from the pellet and stored at − 40 °C. Fecal water samples were thawed and centrifuged at 18,000g for 
10 min at 4 °C. A total of 100 μl fecal water was mixed with 400 μl of deuterium oxide  (D2O) and 100 μl of 0.2 M 
sodium phosphate buffer (pH = 7.4) containing 0.01% TSP (3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium 
salt) and 3 mM  NaN3. After vortexing, 580 μl was transferred to an NMR tube with an outer diameter of 5 mm 
pending 1H NMR spectral acquisition.
1H NMR spectra of fecal water samples were acquired using a Bruker 600 MHz spectrometer (Bruker, Rhein-
stetten, Germany) at the operating 1H frequency of 600.13 MHz at a temperature of 300 K. A standard NMR 
pulse sequence (recycle delay-90°-t1-90°-tm-90°-acquisition) was applied to acquire one-dimensional 1H NMR 
spectral data, where  t1 was set to 3 μs and  tm (mixing time) was set to 10 ms. The water peak suppression was 
achieved using selective irradiation during a recycle delay of 2 s and  tm. A 90° pulse was adjusted to ~ 10 μs. A 
total of 128 scans were collected into 64 k data points with a spectral width of 20 ppm. The standard parameters 
used for these spectral acquisitions have previously been  reported64,65.
Metabolic data have been submitted to the MetaboLights  database66 under accession number MTBLS2051.
High-performance liquid chromatography (HPLC). Amino acids. Amino acids were quantified in 
fecal water prepared by weighing the fecal sample and mixing it with four parts of sodium phosphate buffer 
[pH = 7.4], vortexing and centrifugation at 20,000g at 4 °C for 30 min. Fecal water (50 µl) was mixed with 24% 
sulfosalicylic acid and centrifuged at 20,000g at 4 °C to remove proteins. Amino acids were measured using a 
gradient reversed-phase HPLC system with precolumn derivatization with o-phtalaldehyde (Pierce) and 3-mer-
captopropionic acid (Sigma), and fluorescence detection. Separation was done using 2 serial coupled BDS Hy-
persil C18 columns (150 × 4.8 mm, 3 µm particles, Thermo Scientific, flowrate 0.7 ml/min) and linear gradient of 
solvent A and B (from 10% B at start to 100% B at the end linearly). Solvent A was 12.5 mM sodium phosphate 
(pH 7.0) + 0.005% tetrahydrofuran and solvent B was 6 mM sodium phosphate (pH 7.0) + 0.07% tetrahydro-
furan + 40%  acetonitrile67. For normalization purposes we used norvaline as an internal standard.
Bile acids. Feces was freeze dried overnight. Feces were diluted 1:10 on a weight:volume basis with 50% Tert-
Butanol solution, mixed, sonicated, and centrifuged at 3500 g. Supernatant was freeze-dried overnight and re-
suspended in 300 µl 25% Methanol. Bile acids were separated and quantified by reverse-phase HPLC, which 
was an adaptation to the method used by Kunne et al.68. 100 µl sample was applied to a Hypersil C18 HPLC 
column (internal diameter: 3 µm, column length: 15 cm; Thermo Scientific, Breda, The Netherlands) operated 
at 20 °C. The starting eluent consisted of 6.8 mM ammonium formiate (pH 3.9), followed by a linear gradient or 
isocratic elution with acetonitrile at the indicated concentration: 28% (1 min), 38% (13 min), 42% (19 min), 61% 
(20 min), 63% (25 min), 80% (28 min), 80% (31 min) and 0% (33 min). The flow rate was 0.8 mL per minute. 
Detection was performed using a Charged aerosol detector (ThermoFisher). Quantification of the different bile 
salt species was performed by using a calibration curve for all different bile salt species.
Real time cell growth and adherence assay. The effect of metabolites on epithelial cell proliferation 
and adhesion was performed using a label-free real-time cell analysis platform (xCELLigence; Roche Applied 
Science, Indianapolis, IN) as previously  described69. Each well of a 16 well E-plate received, 100 μl complete 
Dulbecco’s Modified Eagle Medium (DMEM) culture medium supplemented with metabolites of interest, and 
background impedance was measured over 24 s. Caco-2 cells were cultured until confluent, trypsinized and sus-
pended in DMEM supplemented at 20,000 cells/ml. Resuspended cells (100 μl) were added to the E-plate wells. 
14
Vol:.(1234567890)
Scientific Reports |        (2020) 10:18879  | https://doi.org/10.1038/s41598-020-75306-z
www.nature.com/scientificreports/
After 30 min of incubation at room temperature, the plate was placed into the cell culture incubator (37 °C, 5% 
 CO2). Control wells received DMEM medium only. Cell proliferation and adhesion was measured every 30 min 
for 72 h by determining the cell index using the xCELLigence system software version 1.2.170.
Monocyte immunological response assay. Primary monocytes were isolated from whole blood buffy 
coats in 2 steps: (1) Ficoll was added under the buffy coat layer and spun down (2000 RCF, acc. 3, decl. 0, 20 min) 
and the separated layer of peripheral blood mononuclear cells (PBMC) were aspirated an re-suspended, (2) 
PBMC were incubated (90 min, 37 °C, 5%  CO2) after which culture plates were washed and remaining mono-
cytes loosened with EDTA and re-suspended and plated at 500.000 cells/well in 6 well plates (1.5 ml/plate). 
Monocytes were co-cultured with metabolites of interest for 24 h, after which LPS (100 ng/ml) was added. The 
medium was subsequently collected after 4 h and Tumor Necrosis Factor-alpha (TNFα) and Interleukin-6 (IL-6) 
were measured using sandwich ELISA (R&D Systems, Minneapolis, Minn., USA).
Dextran sulfate sodium (DSS) colitis mouse model. C57BL/6  N mice (Charles River Laborato-
ries) were housed and maintained under specific pathogen free conditions in our animal facility at the AMC 
in Amsterdam. Mice were females between 8 and 12 weeks of age at the time of study. Eleven days prior to 
inducing intestinal inflammation with DSS, mice were given chow supplemented with milk protein (n = 10) or 
chow supplemented with amino acids (n = 10) (Mead Johnson Nutrition). Intestinal inflammation was induced 
using 1.5% (w/v) DSS (TdB Consultancy, Uppsala, Sweden) added to the drinking water for 7 days. Fresh DSS 
solutions were prepared daily. Body weights were recorded daily. At the end of the study endoscopy was done 
according to the scoring system described by Becker et al.71. Five features of endoscopic severity were scored: 
‘mucosal thickening’, ‘vasculature’, ‘granularity of the mucosal surface’, ‘fibrin deposits’ and ‘stool appearance’. The 
total endoscopic disease severity score was calculated from the disease components, excluding the stool compo-
nent score (as it was only clearly determinable in 158 of 201 of the videos), with a total score between 0 and 12. 
Subsequent to endoscopy mice were killed and organs collected. Wet weights of colons were recorded together 
with total colon length. Colon weight per cm was used as a disease parameter. Stools were scored as follows: (0) 
normal feces, (1) soft pellets, (2) thin feces, (3) watery diarrhea, (4) bloody diarrhea. Colons were divided in two 
parts longitudinally; one part was used for histology the other part for qPCR analysis.
Histology. Histology was performed as described  previously72. Longitudinally divided colons were rolled, fixed 
in 4% formalin and embedded in paraffin for routine histology. An experienced pathologist evaluated formalin-
fixed hematoxylin tissue sections microscopically, in a blinded fashion. Colons were evaluated, and graded from 
0 to 4 as an indication of incidence and severity of inflammatory lesions based on the extent of the area involved, 
the number of follicle aggregates, edema, fibrosis, hyperplasia, erosion/ulceration, crypt loss and infiltration of 
granulocytes and mononuclear cells. The pathology score was calculated as the total score of the above.
Statistical analysis. Microbiota and metabolomic data were compared between (1) CD patients at T0 and 
healthy controls, (2) between different time points during EEN in CD patients (T0 vs. T1 vs. T2 vs. T3), (3) 
between biochemical responders and non-responders, and (4) between responder or non-responders at follow-
up (T3) and healthy controls.
The statistical analysis for the microbiota data was carried out as described by Dalby et al.  201760, using 
 LEfSe73 and  Metastats74 (p values corrected with Benjamini–Hochberg to account for multiple comparisons)75 to 
assess changes in proportional abundance across OTUs, Genus, Family and Phylum Levels. Differences in overall 
community compositions were analyzed at the OTU level using the Analysis of Molecular Variance (AMOVA) 
function within the mothur software  package76, based on Bray Curtis dissimilarity. The Shannon and inverse 
Simpson diversity indices, which are commonly used to characterizes species diversity in a community based on 
proportional abundance and evenness of the species present, were used to calculate the bacterial diversity within 
each sample using the mothur software  package76. These were compared between cohorts using Mann–Whitney 
tests for CD versus healthy control comparisons, and using the Wilcoxon test for the longitudinal comparisons 
across the term of the EEN intervention. The subsets of samples that were included in each of the comparative 
analyses included in the Results section are shown in Supplementary Table 3.
Multivariate statistical analysis of 1H NMR spectral data were pre-processed (phasing, baseline correction and 
calibration) and imported into MATLAB (R2014a) using an in-house MATLAB script from Imperial College 
London. The shift ranges from − 0.02 to 0.02 ppm, 3.70 to 3.72 ppm and 4.78 to 4.84 ppm were removed to exclude 
TSP, polyethylene glycol (PEG) and water peaks, respectively. Due to the high intensity of PEG compared to 
other peaks in the spectrum, PEG was deemed to be a remnant of the bowel cleansing procedure present in some 
patients and therefore excluded from further analysis. NMR spectra were then aligned using recursive segment-
wise peak  alignment77, normalized using the probabilistic quotient  normalization78 and log-transformed prior to 
Principal Component Analysis (PCA) and Orthogonal Partial Least Squares-Discriminant Analysis (OPLS-DA).
Unit variance scaling method and sevenfold cross validation were used in OPLS-DA models. The model 
parameters were presented as  R2 (percentage of variation explained by the model) and  Q2 (predictivity of the 
models) and p value generated from the permutation tests. Metabolites that are associated with CD, EEN treat-
ment or EEN response were extracted from OPLS-DA models using statistical total correlation spectroscopy 
(STOCSY), the Human Metabolite Database and other literature documenting faecal water metabolites obtained 
from  NMR79–81. Correlation coefficient values (r) were provided based on a selected signal from each metabo-
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Bile acids were categorized into primary and secondary bile acids. The hydrophobicity of the bile acid pool per 
fecal sample was calculated using the bile acid hydrophobicity  index82. Differences in amino acids (individual and 
total concentration) and bile acids (primary and secondary concentration, and bile acid hydrophobicity index) 
were analyzed using t test (2 groups) and one-way ANOVA with Turkey post-hoc test (> 2 groups) for normally 
distributed or Mann–Whitney U (2 groups) and Kruskal–Wallis test with Dunn’s post-hoc test (> 2 groups) for 
non-normally distributed variables.
Cell indexes deriving from XCELLigence and cytokine concentrations deriving from the monocyte immu-
nological response assay were analyzed identical to amino and bile acid data.
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